Under the bilateral trade and investment negotiations with the United States, several developing countries were required to enforce the TRIPS-Plus provisions. The dramatic expansion of these U.S. intellectual property policies through the free trade agreement negotiations has precipitated the intense debate about the merits of these requirements between the United States and its trade partners in the developing world. On one hand, most low-income countries claim that very stringent intellectual property protection for pharmaceuticals will result ...